Grail Inc. Earnings Call Highlights Growth Amid Risks

Grail Inc ((GRAL)) has held its Q1 earnings call. Read on for the main highlights of the call.

Grail Inc.’s latest earnings call struck a cautiously optimistic tone as management balanced strong commercial momentum with ongoing execution risks. Test volumes surged, margins improved and the company highlighted meaningful clinical and regulatory progress, yet investors were reminded of persistent losses, pricing pressure and the mixed signal from the U.K. NHS-Galleri trial.

Robust Test Volumes and Revenue Growth

Galleri test demand accelerated, with more than 56,000 tests sold in the first quarter of 2026, a 50% jump from a year earlier. Screening revenue climbed 37% to $39.8 million, helping lift total revenue to $40.8 million, up 28% year over year when including $1 million from development services.

Improving Unit Economics and Gross Profit

Unit economics showed clear progress as non-GAAP adjusted gross profit rose 38% year over year to $19.7 million. Management attributed the improvement to better leverage of fixed costs from higher testing volumes and lower sample reprocessing, even as pricing headwinds began to emerge.

EBITDA Progress and Ample Cash Runway

Losses remain sizable, but trends are moving in the right direction with adjusted EBITDA at negative $79.9 million, a 19% improvement from a year ago. The company ended the quarter with $823.1 million in cash, giving it what management described as a multi-year runway to fund clinical milestones and commercial expansion.

PMA Acceptance Marks Key Regulatory Milestone

A major highlight was the FDA’s acceptance of Grail’s premarket approval submission for Galleri, formally starting the regulatory review clock. The PMA is backed by data from about 25,000 PATHFINDER 2 participants plus the prevalence round of the NHS-Galleri study and a bridging analysis, and the company described ongoing interactions with regulators as constructive.

Expansive Evidence Base and Upcoming ASCO Data

Grail underscored the breadth of its evidence base, noting that more than 174,000 individuals have been included in studies supporting the PMA. Full results from the 35,000-participant PATHFINDER 2 trial and the 140,000-participant NHS-Galleri study are slated for presentation at ASCO, with management emphasizing consistency between commercial and study testing.

NHS-Galleri Shows Early Detection Benefits

Topline findings from NHS-Galleri pointed to an increase in detection of Stage I and II deadly cancers and a fourfold higher cancer detection rate versus standard screening alone. The company also highlighted reductions in Stage IV diagnoses and emergency presentations, arguing that these patterns support the clinical utility of multi-cancer early detection.

Expanding Partnerships and Health-System Integrations

Commercial reach broadened through partnerships with leading health systems such as Dana-Farber, Cleveland Clinic, Duke, OHSU, Rush and Intermountain, as well as digital-health players including Function Health, Hims & Hers, WHOOP and Everlywell. Integrations with Quest and Athena now enable about 2,000 providers to order Galleri electronically, already generating more than 30,000 tests through those channels.

Sales Force Build-Out to Drive Further Adoption

To capitalize on growing demand, Grail is expanding its field sales and medical teams, with territories set to rise from roughly 90 to 120. Management expects most new representatives to be onboarded and trained by midyear, positioning the company to deepen penetration among providers and employers in the back half of 2026.

Primary Endpoint Miss Clouds NHS-Galleri Narrative

Despite positive secondary signals, the NHS-Galleri trial did not meet its combined primary endpoint of reducing Stage III and IV cancers over three screening rounds. An increase in Stage III detections offset the drop in Stage IV cases, producing a statistically null result that has complicated the overall narrative around the trial’s impact.

Managing Media Scrutiny and Stakeholder Questions

The primary endpoint miss has fueled negative and mixed media coverage, leading to heightened questions from physicians, patients and employer customers. Management said it is prioritizing education and plans detailed data disclosures at ASCO to clarify the trial results and reinforce the potential benefits of earlier cancer detection.

Average Selling Price Pressure Emerges

Average selling prices are under pressure as Grail pursues population-scale pricing and broader discounting programs to spur adoption. The company acknowledged a sequential ASP decline, noting that further modest compression is likely in 2026, though it expects mix shifts and operational efficiencies to partially offset the impact on margins.

Persistent Operating Losses Despite Improvement

The business remains deeply loss-making, with a first-quarter net loss of $93.2 million even after a 12% year-over-year improvement. Management argued that continued investment in commercialization and evidence generation is necessary at this stage, but investors will be watching closely for a path toward narrowing losses as scale builds.

Conservative Outlook Amid Competitive and Policy Risks

Executives pointed to rising promotional activity from peers, including increased direct-to-consumer advertising, as a potential source of noise in the marketplace. They also flagged uncertainty around the timing and structure of future reimbursement policies, noting that while they are optimistic, the path and schedule for broader coverage remain unclear.

Regulatory Timing Adds Planning Uncertainty

While PMA acceptance is a key step, Grail emphasized that regulatory timing remains a wildcard, particularly whether the FDA will convene an advisory committee. Management noted that review timelines could range from roughly six months to well over 10 months, complicating planning for commercial scale-up and investor expectations.

Guidance: Strong Start, Cautious Full-Year Outlook

For 2026, Grail reaffirmed its revenue growth guidance of 22% to 32% despite a robust first quarter that saw revenue up 28% and screening revenue up 37% on a 50% increase in test volume. The company cited uncertainty around the uptake of new digital partnerships, timing of the sales-force expansion, rollout of the Epic Aura integration across roughly 450 eligible health systems and regulatory or coverage milestones, adding that it will revisit guidance after the second quarter.

Grail’s earnings call painted a picture of a company gaining commercial traction while navigating scientific, regulatory and competitive crosscurrents. Strong volume growth, improving margins and a deep evidence base underpin management’s confidence, but investors will be watching execution on sales expansion, pricing discipline and regulatory milestones to determine whether today’s promise translates into durable shareholder value.